1-4 of 4
second line treatment
Close
Sort by
Journal Articles

Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor

Clinical Trials & Observations
Shernan G. Holtan, Andrea L. Hoeschen, Qing Cao, Mukta Arora, Veronika Bachanova, Claudio G. Brunstein, Jeffrey S. Miller, Armin Rashidi, Arne Slungaard, Celalettin Ustun, Gregory M. Vercellotti, Erica D. Warlick, Brian C. Betts, Najla El Jurdi, Fiona He, Chi Chen, Isha Gandhi, John E. Wagner, Bruce R. Blazar, Pamala Ann Jacobson, Ashraf Shabaneh, Jinhua Wang, Angela Panoskaltsis-Mortari, Margaret L. MacMillan, Daniel J. Weisdorf
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1284–1295.
https://doi.org/10.1182/bloodadvances.2019001259
Published: 2020
Includes: Supplemental data
Journal Articles

Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details

Vaishali Sanchorawala
Journal: Blood Advances
Blood Adv (2019) 3 (2): 216–218.
https://doi.org/10.1182/bloodadvances.2018021261
Published: 2019
Journal Articles

Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia

Clinical Trials & Observations
Stephanie Guidez, Julien Labreuche, Elodie Drumez, Loic Ysebaert, Jana Bakala, Caroline Delette, Bénédicte Hivert, Caroline Protin, Hervé Declercq, Mélanie Verlay, Jean Pierre Marolleau, Alain Duhamel, Pierre Morel
Journal: Blood Advances
Blood Adv (2018) 2 (22): 3102–3111.
https://doi.org/10.1182/bloodadvances.2018021287
Published: 2018
Includes: Supplemental data
Journal Articles

How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD

Clinical Trials & Observations
Samantha M. Jaglowski, Bruce R. Blazar
Journal: Blood Advances
Blood Adv (2018) 2 (15): 2012–2019.
https://doi.org/10.1182/bloodadvances.2018013060
Published: 2018